Pfizer (PFE) Cash from Financing Activities (2009 - 2026)

Pfizer (PFE) has reported Cash from Financing Activities for 18 consecutive years, with -$3.7 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Financing Activities fell 14.61% year-over-year to -$3.7 billion in Q2 2026; TTM through Jun 2026 was -$8.4 billion, a 63.33% increase from a year earlier, with the FY2025 full-year figure at -$10.3 billion, up 39.88% from the prior year.
• Cash from Financing Activities was -$3.7 billion for Q2 2026 at Pfizer, down from -$2.9 billion in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $27.2 billion in Q3 2023 and troughed at -$12.0 billion in Q3 2024.
• A 5-year average of -$746.6 million and a median of -$2.8 billion in 2023 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities plunged 134.34% in 2022 and surged 978.33% in 2023, its largest moves.
• Over 5 years, Cash from Financing Activities stood at $2.5 billion in 2022, then jumped by 115.95% to $5.4 billion in 2023, then slumped by 320.98% to -$12.0 billion in 2024, then surged by 104.96% to $596.0 million in 2025, then sank by 714.6% to -$3.7 billion in 2026.
• The last three Cash from Financing Activities figures came in at -$3.7 billion (Q2 2026), -$2.9 billion (Q1 2026), and $596.0 million (Q4 2025), per Business Quant data.